Compare RGT & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGT | MXCT |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.4M | 93.0M |
| IPO Year | N/A | 2021 |
| Metric | RGT | MXCT |
|---|---|---|
| Price | $14.32 | $1.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 12.6K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | $15.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.40 | $0.64 |
| 52 Week High | $14.99 | $2.40 |
| Indicator | RGT | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 60.44 |
| Support Level | $12.50 | $0.77 |
| Resistance Level | $14.68 | $1.16 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 48.32 | 64.10 |
Royce Global Value Trust Inc is a diversified closed-end investment company. The Fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples and energy. Geographically, it has presence in the United Kingdom, Japan, the United States, Canada, France, Hong Kong and Germany.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.